All News

Manufacturers are rethinking patient assistance program architecture amid the economic pressures of the Inflation Reduction Act.

The ruling places a hold on any decisions made by the council, although the government does plan to appeal the ruling.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jiang Li, CEO of Vivalink, continues his conversation with Pharmaceutical Executive, this time discussing the impact of continuous monitoring on patient adherence.

Jeanne Marrazzo, MD, FIDSA, MPH, CEO of the Infectious Diseases Society of America discusses the growing measles outbreak in the United States, which has surpassed 730 cases and represents the largest surge in decades.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical development appearing to be part of a broader effort to strengthen trial evidence.

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.

Vivalink’s CEO Jiang Li, PhD, discusses the importance of including as much information with clinical data as possible.

Sentynl Therapeutics has licensed an investigational drug targeting progeria, a rare genetic disorder that causes rapid aging in children, adding a second potential therapy to its portfolio focused on the disease.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering the scientific bar.

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.

Aravo CCO Dave Rusher discusses the risk of third-party AI usage at pharma companies.

A nationally representative survey of more than 20,000 U.S. adults found that 33% made at least one daily spending trade-off to pay for healthcare in the past year

Arexvy is now approved for adults aged 18 to 49 with underlying conditions that elevate their risk of severe RSV disease.

In today's Pharmaceutical Executive Daily, Senate Democrats press major pharmaceutical companies for transparency on the terms of their most-favored-nation pricing deals with the Trump administration, a new analysis examines the gap between the promise and the reality of Europe's Joint Clinical Assessment framework, and Eli Lilly issues a public safety warning about compounded tirzepatide products mixed with vitamin B12.

How organizations can gain an edge in the enterprise transformation to unified analytics that's accelerating across pharma.

Industry experts across the biotech sector discuss the latest trends impacting emerging biotech companies, including the challenges of early-stage biotech start-ups, AI integration across the sector, and the most recent innovations in drug discovery.

Testing reveals that compounded tirzepatide products mixed with vitamin B12 contain a chemical impurity of unknown toxicity.

Vincent Hennemand discusses using these types of therapies to develop treatments for autoimmune conditions.

In today's Pharmaceutical Executive Daily, the FDA issues new draft guidance aimed at reducing the cost and complexity of biosimilar development, Novo Nordisk responds to an FDA warning letter stemming from a 2025 inspection of its U.S. headquarters, and Pharmaceutical Executive's latest analysis examines the state of the biopharma industry as it navigates a period of cautious momentum.

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics, factors that favor strategically driven growth pursuits ahead.

FDA cites systemic failures in how the company tracked and reported adverse drug events across several of its medicines, including semaglutide.

Leaning into a future downward pricing environment in pharma.

FDA issued draft guidance that would eliminate certain clinical pharmacokinetic studies from the biosimilar development process.

ICON Biotech surveyed 163 biotech leaders in North America, EMEA and APAC to see how they are responding to the headwinds.

Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law PLLC, notes FDA’s single-trial approval pathway may accelerate development, but manufacturers face heightened litigation risk, pricing uncertainty and safeguards.